<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365857</url>
  </required_header>
  <id_info>
    <org_study_id>thecaldex</org_study_id>
    <nct_id>NCT02365857</nct_id>
  </id_info>
  <brief_title>Intrathecal Dexmedetomidine With Bupivacaine for Spinal Anesthesia in Cesarean Section</brief_title>
  <official_title>Effects of Intrathecal Dexmedetomidine on the Perioperative Clinical Profile of Bupivacaine-induced Spinal Anesthesia for Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Controlled, Double blind study aiming to evaluate the analgesic potentials and
      side effect profile of different dose levels of Dexmedetomidine added to subarachnoid
      bupivacaine in full-term pregnant women undergoing elective cesarean section using spinal
      anesthesia. The investigators ultimate goal is to find out the least effective dose which
      will be associated with minimal or no side effects. The primary outcome will be the time to
      two sensory block segment regression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alpha 2-agonists are non-opioid adjuvants with a significant role in extending the analgesic
      duration of subarachnoid block. When clonidine or Dexmedetomidine was added to intrathecal
      local anesthetics, the regression of sensory and motor blocks increased dose-dependently.
      Further, a recent meta-analysis including seven randomized controlled studies reported an
      increase in the duration of analgesia and reduced morphine requirement after the concomitant
      subarachnoid administration of clonidine.

      Animal studies demonstrated that Dexmedetomidine added to bupivacaine significantly enhanced
      the duration of sensory and motor blockade of sciatic nerve block. Histo-pathological
      examination proved that all of the nerves analyzed had normal axons and myelin at 24 h and 14
      days after the peri-neural administration of Dexmedetomidine. Several clinical studies
      confirmed the analgesic potentials and safe neurological outcome of neuraxially administered
      Dexmedetomidine in the non-obstetric settings while intrathecal clonidine proved to be a
      useful analgesic adjunct for spinal anesthesia in patients undergoing cesarean section. But
      to the best of the investigator knowledge the effects of intrathecal Dexmedetomidine on the
      perioperative clinical profile of bupivacaine-induced spinal anesthesia were not studied
      before in the obstetric patient population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to two sensory block segment regression.</measure>
    <time_frame>70 min</time_frame>
    <description>Define the start of regression of the level of sensory block</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The peak sensory level of the block.</measure>
    <time_frame>10 min</time_frame>
    <description>By Pin Prick testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from intrathecal injection to peak sensory block level.</measure>
    <time_frame>10 min</time_frame>
    <description>Define the speed of onset of the block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to S1 level sensory regression.</measure>
    <time_frame>70 min</time_frame>
    <description>Define duration of the block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of motor block.</measure>
    <time_frame>24 h</time_frame>
    <description>By Modified Bromage Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative hemodynamic variables.</measure>
    <time_frame>24 h</time_frame>
    <description>Detect frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total dose of ephedrine/atropine required to maintain hemodynamic stability.</measure>
    <time_frame>24 h</time_frame>
    <description>Detect frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The amount of lactated Ringer's solution required intraoperatively to maintain normal Blood pressure range</measure>
    <time_frame>24 h</time_frame>
    <description>Detect frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation (the need for O2 supplementation)</measure>
    <time_frame>24 h</time_frame>
    <description>Detect frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative analgesic supplementation</measure>
    <time_frame>70 min</time_frame>
    <description>Define quality of the block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first postoperative rescue analgesic request</measure>
    <time_frame>24 h</time_frame>
    <description>Define duration of analgesia by the block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain scores for 24 hours</measure>
    <time_frame>24 h</time_frame>
    <description>Define duration of analgesia by the block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of administration of postoperative analgesics</measure>
    <time_frame>24 h</time_frame>
    <description>Define duration of analgesia by the block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative sedation scores</measure>
    <time_frame>24 h</time_frame>
    <description>Detect frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects (nausea, vomiting, shivering, pruritus, respiratory depression, and desaturation)</measure>
    <time_frame>24 h</time_frame>
    <description>Detect frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New born Apgar Score</measure>
    <time_frame>5 min</time_frame>
    <description>Detect any effects on the new born at different dose levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of motor block.</measure>
    <time_frame>24 h</time_frame>
    <description>By Modified Bromage Score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early postoperative hemodynamic variables.</measure>
    <time_frame>24 h</time_frame>
    <description>Detect frequency of side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of postoperative analgesics</measure>
    <time_frame>24 h</time_frame>
    <description>Define duration of analgesia by the block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative sedation scores</measure>
    <time_frame>24 h</time_frame>
    <description>Detect frequency of side effects</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Anesthesia, Spinal</condition>
  <arm_group>
    <arm_group_label>DEX-5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine &amp; Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 5 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEX-10</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine &amp; Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 10 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DEX-15</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexmedetomidine &amp; Bupivacaine. Patients will receive intrathecal 12.5 mg isobaric bupivacaine and 15 μg Dexmedetomidine using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine Only. Patients will receive intrathecal 12.5 mg isobaric bupivacaine only using a total volume of injectate of 2.5 ml, and intrathecal injections will be given over approximately 10 to 15 seconds.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine &amp; Bupivacaine.</intervention_name>
    <description>Intrathecal injection of Dexmedetomidine &amp; Bupivacaine.</description>
    <arm_group_label>DEX-5</arm_group_label>
    <arm_group_label>DEX-10</arm_group_label>
    <arm_group_label>DEX-15</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Only.</intervention_name>
    <description>Intrathecal injection of Bupivacaine only.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Full-term pregnant women.

          -  Elective cesarean section using spinal anesthesia.

          -  Singleton gestation.

          -  American Society of Anesthesiologists (ASA) physical status classes I and II.

        Exclusion Criteria:

          -  Preterm pregnancy (&lt;37 wks gestation).

          -  Multiple gestation.

          -  Cardiovascular disease (e.g., preeclampsia, hypertension) and the use of
             antihypertensive medication.

          -  Conditions that preclude spinal anesthesia.

          -  Failed spinal block and conversion to general anesthesia.

          -  A history of established chronic pain.

          -  Drug addiction.

          -  A psychiatric disorder.

          -  Inability to communicate effectively.

          -  Asthma and allergy to non-steroidal anti-inflammatory drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2015</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>January 30, 2016</last_update_submitted>
  <last_update_submitted_qc>January 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Professor Mohamed Abdulatif Mohamed</investigator_full_name>
    <investigator_title>Abdulatif M.</investigator_title>
  </responsible_party>
  <keyword>spinal anesthesia</keyword>
  <keyword>caesarian section</keyword>
  <keyword>Dexmedetomidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

